Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer

The response to treatment is substantially varied between individual patients with ovarian cancer. However, chemotherapy treatment plans rarely pay sufficient attention to the mentioned factors. Instead, standardized treatment protocols are usually employed for most ovarian cancer patients. Variations in an individual's sensitivity to drugs significantly limit the effectiveness of treatment in some patients and lead to severe toxicities in others. In the present investigation, a nanotechnology‐based approach for personalized treatment of ovarian carcinoma (the most lethal type of gynecological cancer) constructed on the individual genetic profile of the patient's tumor is developed and validated. The expression of predefined genes and proteins is analyzed for each patient sample. Finally, a mixture of the complex nanocarrier‐based targeted delivery system containing drug(s)/siRNA(s)/targeted peptide is selected from the pre‐synthesized bank and tested in vivo on murine cancer model using cancer cells isolated from tumors of each patient. Based on the results of the present study, an innovative approach and protocol for personalized treatment of ovarian cancer are suggested and evaluated. The results of the present study clearly show the advantages and perspectives of the proposed individual treatment approach. A personalized treatment of ovarian cancer tailoring therapies based on individual genetic tumor profiles is proposed. The expression of predefined genes/proteins is analyzed in samples of the patient's tumor tissue, individual molecular targets are selected, and a mixture of nanoparticles containing drug(s)/siRNA(s)/targeted peptide is prepared and used for the treatment. The approach is validated using an orthotopic mice tumor model.